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Abstract. Distant metastases account for the majority of 
cancer-related deaths in breast cancer. The rate and site of 
metastasis differ between estrogen receptor (ER)-negative 
and ER-positive tumours, and metastatic fate can be very 
diverse even within the ER-negative group. Characterisation 
of new pro-metastatic markers may help to identify patients 
with higher risk and improve their care accordingly. Selectin 
ligands aberrantly expressed by cancer cells promote metas-
tasis by enabling interaction between circulating tumour cells 
and endothelial cells in distant organs. These ligands consist 
in carbohydrate molecules, such as sialyl-Lewis x antigen 
(sLex), borne by glycoproteins or glycolipids on the cancer cell 
surface. We have previously demonstrated that the molecular 
scaffold presenting sLex to selectins (e.g. glycolipid vs. glyco-
proteins) was crucial for these interactions to occur. Moreover, 
we reported that detection of sLex alone in breast carcinomas 
was only of limited prognostic value. However, since sLex was 
found to be carried by several glycoproteins in cancer cells, 
we hypothesized that the combination of the carbohydrate 
with its carriers could be more relevant than each marker 
independently. In this study, we addressed this question by 
analysing sLex expression together with two glycoproteins 
(BST-2 and LGALS3BP), shown to interact with E-selectin in 
a carbohydrate-dependent manner, in a cohort of 249 invasive 
breast cancers. We found both glycoproteins to be associated 
with distant metastasis risk and poorer survival. Importantly, 
concomitant high expression of BST-2 with sLex defined a sub-
group of patients with ER-negative tumours displaying higher 
risks of liver and brain metastasis and a 3-fold decreased 
survival rate.
Introduction
The 5-year overall survival of breast cancer patients with distant 
metastasis is 23.4% (http://seer.cancer.gov/ for details see ref. 1) 
and once detected, metastatic breast cancer is incurable. Distant 
metastases arise from circulating cancer cells that migrate from 
the blood stream to colonise a distant organ (extravasation) (2). 
Specific inhibition of cancer cell extravasation would therefore 
potentially lead to a decrease in the incidence of metastasis. 
Thus, delineating the molecular mechanisms involved in 
this process is one of the crucial challenges for breast cancer 
treatment.
One such mechanism is the interaction between sialyl-
Lewis x (sLex) antigen expressed by cancer cells and the 
selectins expressed by endothelial or circulating immune 
cells (3). There is a compelling body of evidence that 
sLex/selectin interaction is involved in metastatic progression 
in several types of solid tumours including gastric (4), lung (5) 
and prostate (6) cancers. However, the relationship in breast 
cancer metastasis remains controversial (7).
We have previously reported that sLex was over-expressed 
in estrogen receptor (ER)-negative breast tumours compared to 
ER-positive ones. Although ER-negative cancers are known to 
typically be of higher grade and intrinsically more aggressive 
and more often develop metastatic foci, we found no evidence 
that sLex was correlated with metastatic behaviour either in the 
ER-negative or the ER-positive group (7).
This lack of association led us to question the context of 
expression of sLex in breast cancer cells, asking whether the 
scaffold carrying sLex (e.g. glycosphingolipids or specific 
glycoproteins) influenced its role in metastasis. Indeed, we 
reported that rolling on endothelial cells was more efficient 
when sLex was carried by glycoproteins rather than glyco-
lipids (7). However, sLex was found to be carried by several 
membrane bound glycoproteins in a breast cancer cell line that 
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displayed selectin-dependent rolling on endothelial lining. We 
identified two of these glycoproteins as tetherin, also known 
as bone marrow stromal antigen 2 (BST-2), and the galectin-
3-binding protein (also named MAC-2BP) encoded by the 
LGALS3BP gene (7). Subsequently, Shirure et al have shown 
that MAC-2BP carrying sLex was functionally involved in 
ZR-75-1 rolling on HUVECs cultured as monolayer (8).
In the present study, we assessed the expression of sLex, 
BST-2 and LGALS3BP in a cohort of 249 invasive breast 
cancer patients. We investigated whether the combination of 
sLex with one or other of its known carriers has a bearing on 
the prognostic value of sLex.
Materials and methods
Human samples. The samples used in the study were provided 
by the King's Health Partners Cancer Biobank under their 
generic ethics approval from National Research Ethics 
Service, Committee East of England-Cambridge East, refer-
ence 12/EE/0493. Under this approval the Biobank are also 
able to provide pseudo-anonymised samples for research 
without informed consent if they were collected before 
September 2006. All tissue samples used in the study were 
collected prior to Human Tissue Act 2004.
Tissue microarray (TMA) construction and analysis. 
Formalin-fixed paraffin wax embedded tissue from consecu-
tive cases of invasive breast carcinoma dating from 1990 to 
1995 (n=400) were selected from the King's Health Partners 
Cancer Biobank. Clinical data, including date and site of 
metastatic recurrence, were collected and validated for each 
sample. From each block 0.6-mm diameter cores were marked 
on haematoxylin and eosin-stained slides and the invasive 
cancer subsequently sampled using the Beecher TMArrayer 
(Wisconsin, MA, USA) and placed into replicate, 100 core 
TMA blocks. Sections from two duplicate TMA blocks were 
cut at 3 µm and dried overnight at 37˚C. Sections were baked 
for 2 h at 60˚C, blocked using 10% bovine serum albumin 
in PBS and stained with anti-sLex monoclonal antibody 
(mAb) HECA-452 (7) (BD Biosciences, Oxford, UK) at a 
concentration of 1 µg.ml-1, anti-LGALS3PB mAb 6B7 (Novus 
Biologicals, Cambridge, UK) at a concentration of 0.2 µg.ml-1, 
or anti-BST-2 polyclonal antibody (9) (Novus Biologicals) at 
a concentration of 0.2 µg.ml-1. The staining was performed 
using a Ventana Ultra automat (Roche, Rotkreuz, Switzerland) 
running on Program U33. Primary antibodies were incubated 
for 32 min on slides, without heating, followed with appro-
priate secondary and tertiary reagents (UltraView universal 
DAB Detection kit; Dako, Ely, UK). Staining conditions 
were optimised for each antibody using a panel of pellets of 
breast cancer cell lines that were formalin-fixed and paraffin- 
embedded (Fig. 1). This panel included the ZR-75-1 for which 
both BST-2 and LGALS3BP staining were positive, according 
to the fact that these proteins were immuno-precipitated 
from this particular cell line (7). The staining of biopsies was 
independently scored by two observers (S.J. and S.E.P., breast 
pathologist). Score was calculated as the core average of the 
product IxP, where I is the intensity of the staining (0, 1, 2 or 3) 
and P the percentage (0-100%) of stained tumour cells (see 
Fig. 2 for illustration). Cases where there was disagreement 
between the observers were reviewed and consensus reached 
on a multiheaded microscope. Tumours were classified as 
‘low’ when ≤ to the median and ‘high’ otherwise. Statistical 
analyses were carried on using Prism5 (Graph-Pad software).
Depending on technical issues (e.g. cores damaged or 
lost during process, quality of the tissue present in the cores) 
unbiased observation could only be performed for about 
350 samples for each marker. To avoid any cohort bias, we 
chose to include in the statistical analysis only the samples 
for which observation could have been made for each of the 
three markers. When cross-referenced, averaged scores for 
each of the targets were validated for 249 tumours out of the 
400 initially included. The details of clinical and biological 
features of this cohort is given in Table I. Overall, this cohort 
fits the known statistics of the pathology regarding the rate 
of expression biomarkers (10) or the survival rates (1), thus 
excluding bias from the cohort selection. Unfortunately, 
Table I. Clinical and biological features of the cohort of 
249 patients.
Characteristics Data
Median age at diagnosis: year 57.0 (Min: 29.0, Max 94.0)
Average tumour size: cm 2.64
Histological grade: n (%)
  G1  41 (16.5)
  G2 93 (37.3)
  G3 97 (39.0)
  ND 18 (7.2)
Lymph node Involvement: n (%)
  Positive 128 (51.4)
  Negative 108 (43.4)
  ND 13 (5.2)
Estradiol receptor (ER): n (%)
  Positive 189 (75.9)
  Negative 57 (22.9)
  ND 3 (1.2)
Progesterone receptor (PR): n (%)
  Positive 153 (61.4)
  Negative 93 (37.3)
  ND 3 (1.2)
HER2: n (%)
  Positive 110 (44.2)
  Negative 25 (10.0)
  ND 114 (45.8)
Median follow-up: months 148.0
Local recurrences: n (%) 37 (14.9)
Distant recurrences: n (%) 73 (29.3)
Breast cancer specific death: n (%) 68 (27.3)
ND, not documented.
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HER2 expression status was only available for 134 (53%) 
of the samples rendering difficult to specifically address the 
triple-negative group (17 samples, 12.7%) within this cohort. 
We thus decided to stratify our cohort based on the sole ER 
expression for subsequent analysis.
Results
Staining and scoring of biopsies. For all three antibodies, the 
observed staining was mainly cytoplasmic with membrane 
signal observable when the cells were strongly stained (Fig. 2). 
Variation of staining intensities allowed to classify each 
sample according to the level of expression of each marker (11). 
The frequency distributions of the scores were distinct when 
comparing the three markers (Fig. 3A) and quite different 
from the Gaussian-type frequency distribution commonly 
observed when measuring gene expression (Fig. 3B). Due to 
the asymmetrical score distributions, we chose to use median 
to discriminate between ‘Low’ and ‘High’ scores and compare 
group of tumours of the same size if possible. Median scores 
were 2.5 for sLex and 200 for LGALS3BP. Median was also 
200 for the BST-2 group, but the very homogeneous staining in 
this group resulted in 91 tumours being scored 200, making the 
use of the median inappropriate to split the series in two equal 
groups. After comparing the survival of the patients according 
to the 25 and 75% percentile scores (Fig. 3C) we chose to use 
the highest quartile (score >202.5) to define our ‘High’ BST-2 
group. Although we identified both proteins as carriers of sLex 
in a breast cancer cell line (ZR-75-1), scores of sLex did not 
significantly correlate with either BST-2 (Pearson r2=0.017, 
p=0.042) or LGALS3BP (Pearson r2=0.002, p=0.445). This 
suggests that in breast tumours, the occurrence of the high 
expression of either carrier is independent of the occurrence of 
high sLex expression and vice versa.
Correlation with clinical features. We first analysed the 
association of each of the three markers with several histo-
logical and clinical features of the tumours (Table II). As 
previously reported (12), sLex high expression correlated with 
ER-negativity, lymph node (LN) involvement, and high grade. 
We also observed a correlation with progesterone receptor 
(PR) negativity. When considering the entire cohort, BST-2 
and LGALS3BP did not correlate with any of the tested 
features.
Figure 1. Immunohistochemistry performed on fixed paraffin-embedded 
cell pellets from various breast cancer cell lines. Anti-BST-2 and Anti-
LGALS3BP antibodies were used as described in Material and methods. 
BST-2 expression is observed in every cell line, albeit at various inten-
sity, while LGALS3BP staining is more heterogeneous across the panel. 
Bars: 50 µM.
Figure 2. Examples of Low and High staining obtained in TMA to illustrate 
the calculation of the score. Intensity of the staining was determined by 
cross-examination of all the cores stained for each given slide. Scores are cal-
culated based on the percentage of tumour cells positively stained excluding 
the non-tumoural content of the core. Scores reported by both examiners 
(SJ and SP) are indicated for each sample together with their averages (Av.). 
Bar: 60 µM.
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Both BST-2 and LGALS3BP high expression correlated with 
earlier time of metastasis and poor prognosis. Kaplan-Meier 
analyses were performed for each marker individually after 
ER stratification (Fig. 4). sLex on its own did not associate with 
either distant metastasis-free survival (DMFS) or breast cancer 
specific survival (BCSS), as we have previously reported. 
However, strikingly, both BST-2 and LGALS3BP high expres-
sion predicted earlier development of distant metastasis and 
shorter patient survival in the ER-negative group, but not in 
the ER-positive subset of patients (Fig. 4). While none of the 
markers were associated with DM when analysing the cohort 
as a whole, both BST-2 and LGALS3BP correlated with DM 
within the ER-negative group (p=0.0270 and p=0.0353 Fisher's 
exact test, respectively). This suggests that both glycoproteins 
are involved in ER-negative tumour progression independently 
of sLex expression.
BST-2 significantly alters the organotropism of ER-negative 
metastasis. We previously reported that ‘very-high’ (i.e. score 
of >60) expression of sLex in ER-positive tumours drove 
metastasis to the bone (12). In the present study metastatic 
ER-positive tumours with very-high sLex similarly colonised 
bone more frequently than those with low sLex expression 
(87.5 and 52.6%, respectively).
ER-negative tumours colonised distant organs at various 
frequencies: lung (8.9%), liver (12.5%), bone (14.3%), brain 
(17.9%) and other distant organs (23.2%) such as distant lymph 
nodes (contra-lateral or mediastinal), pleura or skin. These 
frequencies were compared between groups displaying high or 
low expression of sLex, BST-2 and LGALS3BP (Fig. 5). Taken 
independently, variation in occurrence of metastasis for each 
site was not found to be significantly associated to the expres-
sion of any of the tested markers. However, high expression of 
Table II. Correlation of antigen expression with biological features of the tumours.
 sLex BST-2 LGALS3BP --------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------
 Lowa High  Low High  Low High --------------------- ---------------------  ---------------------- ---------------------  --------------------- --------------------
Features nb %c n % p-value n % n % p-value n % n % p-value
ERd
  Pos 110 58.2 79 41.8 0.010 140 74.1 49 25.9 NS 102 54.0 87 46.0 NS
  Neg   22 38.6 35 61.4    45 78.9 12 21.1    33 57.9 24 42.1
PRd
  Pos 92 60.1 61 39.9 0.012 111 72.5 42 27.5 NS 85 55.6 68 44.4 NS
  Neg 40 43.0 53 57.0    74 79.6 19 20.4  50 53.8 43 46.2
HER2d
  Pos 13 52.0 12 48.0 NS 17 68.0   8 32.0 NS 12 48.0 13 52.0 NS
  Neg 55 50.0 55 50.0  81 73.6 29 26.4  61 55.5 49 44.5
LNd
  Pos 60 47.6 66 52.4 0.039 95 75.4 31 24.6 NS 71 56.3 55 43.7 NS
  Neg 71 61.2 45 38.8  89 76.7 27 23.3  59 50.9 57 49.1
TSd
  <2 cm 54 54.5 45 45.5 NS   69 69.7 30 30.3 NS 58 58.6 41 41.4 NS
  >2 cm 78 53.1 69 46.9  117 79.6 30 20.4  77 52.4 70 47.6
DMd
  Pos   34 46.6 39 53.4 NS   56 76.7 17 23.3 NS 41 56.2 32 43.8 NS
  Neg 100 56.8 76 43.2  132 75.0 44 25.0  96 54.5 80 45.5
Gradee
  1 23 56.1 18 43.9 <0.001 33 80.5   8 19.5 NS 25 61 16 39.0 NS
  2 61 65.6 32 34.4  68 73.1 25 26.9  50 53.8 43 46.2
  3 36 37.1 61 62.9  76 78.4 21 21.6  51 52.6 46 47.4
Agee
  <50 yrs. 34 47.9 37 52.1 NS 49 69.0 22 31.0 NS 38 53.5 33 46.5 NS
  50-70 yrs. 72 57.6 53 42.4  97 77.6 28 22.4  69 55.2 56 44.8
  >70 yrs. 28 52.8 25 47.2  42 79.2 11 20.8  30 56.6 23 43.4
aOn the basis of median and quartile scores detailed in result section. bn, number of tumours; c%, percentages of tumours displaying Low 
or High levels of markers for each clinical feature considered. dCorrelation calculated using Fisher's exact test on Prism5 software. NS, not 
significant. eCorrelation calculated using χ2 test on Prism5 software.
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BST-2 seemed to generally affect the distribution of metastasis 
across the board. High expression of BST-2 was associated 
with increased metastasis in liver (2.8-fold) and brain (1.4-fold) 
while metastasis was decreased in lung (1.3-fold) and bone 
(1.9-fold). By comparison, the two other markers had limited 
effects. High sLex expression seemed to follow the same trend 
as high BST-2, especially for liver and lung metastasis. High 
expression of LGALS3BP tended to be associated with an 
overall higher frequency of metastasis without affecting the 
tropism. As a result, we found that expression of BST-2 signifi-
cantly altered the pattern of metastasis when compared to the 
two other markers (Chi-square test, p=0.0246).
Combined expression of BST-2 and sLex further improves 
BST-2 prognostic value. Although we did not find sLex 
correlation with its carriers in tumours, there is, nonethe-
less, a discrete fraction of patients whose tumours displayed 
high sLex expression together with high expression of BST-2 
(10.6% of patients) and/or LGALS3BP (24.4%). Due to the 
documented function of sLex carried by these proteins as 
E-selectin ligand (7,8), we investigated the prognostic value 
of these combinations of markers in our series.
We analysed metastasis-free and breast cancer specific 
survival of patients within groups displaying high sLex expres-
sion together with high expression of one or the other of its 
carriers (BST-2 or LGALS3BP) compared to the rest of the 
patients (Fig. 6).
This stratification did not bear any significance for the 
patients with ER-positive tumours. In the ER-negative group, 
the combination of sLex with LGALS3BP did not improve, and 
Figure 3. Score distribution and analysis. (A) Histograms showing the frequency distribution of the staining scores is non-symmetrical for LGALS3BP and 
sLex and clearly different for all three markers. Pecentile, median and mean are reported below each graph for each marker. (B) Histograms showing the 
frequency distribution of gene expression detected by RNA microarray. Data were generated by Desmedt et al (30) and show that the distribution of the 
signal measuring transcript levels are not distributed the same way than the staining scores. (C) Survival (breast cancer specific survival) analysis of patients 
according to the level of expression of BST-2 detected by immunostaining in ER-positive or ER-negative tumours. 1st quartile, 0-175; 2nd and 3rd quartiles, 
>175 to 202.5; 4th quartile, >202.5.
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actually reduced, the prognostic value of LGALS3BP. This 
suggests that the LGALS3BP function in ER-negative breast 
cancer metastasis is independent of sLex expression. This was 
surprising since sLex bearing LGALS3BP has been shown to 
be involved in the rolling of the ZR-75-1 breast cancer cell line 
on endothelial cells (8). However, LGALS3BP, as a secreted 
protein, has been linked to cancer metastasis through inter-
actions with other proteins such as Tem1 (13) or galectins 1 
and 3 (14-16). These multiple mechanisms may explain why 
LGALS3BP on its own bears some prognostic value, as previ-
ously reported (17), while the sLex/LGALS3BP does not.
In contrast, the sLex/BST-2 combination retained (and 
even increased) statistical significance in analysis for both 
metastasis and patient survival, despite the fact the sLex/BST-2 
group was reduced to 8 patients. Computation of Hazard Ratio 
showed an increase of risk when sLex was combined to BST-2, 
for both BCSS (from 3.654 to 4.566) and DMFS (from 3.961 
to 7.070), indicating that the patients displaying both markers 
concomitantly were more rapidly at risk than the others 
(Table III). By contrast, the same comparison performed using 
LGALS3BP with sLex did not show any increase. The combi-
nation of BST-2 with sLex identified a sub-group (14%) of 
ER-negative patients with an 80% risk of metastasis at 5 years, 
twice the level in the patients with tumours not over-expressing 
both markers simultaneously. The patients with ER-negative 
carcinomas expressing both sLex and BST-2 had only a 20% 
survival at 10 years, about three times less than other patients 
with ER-negative cancers. This may be due to the metastatic 
tropism associated with BST-2, possibly enforced by sLex, 
since brain and liver metastasis are more rapidly lethal than 
bone and lung metastasis (18).
By comparison, stratification based on the high expres-
sion of both BST-2 and LGALS3BP did not result in a better 
prediction of metastasis or survival than each of the markers 
taken individually (Fig. 7).
Influence of treatment of ER-negative patients on survival 
analyses. Detailed review of the adjuvant therapy given to 
the ER-negative groups revealed that half of the patients (28) 
received chemotherapy drugs, while the other half (29) was 
only treated with Tamoxifen as it was routinely performed 
during the nineties (see Table IV for details). We found no 
Figure 4. Correlation of sLex, BST-2 and LGALS3BP expression with distant metastasis-free survival (DMFS) and breast cancer specific survival (BCSS) 
according to ER status. Number of patients included is indicated next to each DMFS curve. p-values were calculated using Grehan-Breslow-Wilcoxon test 
(Prism5).
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differences in DMFS or BCSS when comparing these two 
arms, thus excluding any treatment bias in the results reported 
above. We further explored the effect of each protocol (no 
chemotherapy vs. chemotherapy) on the aggressive High 
BST-2/sLex sub-population. The results seemed to indicate that 
the patients belonging to the poor prognosis group fared better 
when treated with chemotherapy compared to those treated 
only with Tamoxifen (Fig. 8). Albeit statistically significant, 
this analysis was performed with a very limited number of 
samples and should be considered with appropriate reserve.
Discussion
In this study, we retrospectively assessed the prognostic 
significance of two membrane bound glycoproteins, BST-2 
and LGALS3BP, in breast cancer metastasis and survival. Both 
proteins were chosen based on the fact that they were found to 
be E-selectin ligands, when carrying the carbohydrate deter-
minant known as sialyl-Lewis x (sLex) antigen, and potentially 
involved in blood borne metastasis. We previously investigated 
the expression of sLex in breast cancer and found this glycan 
overexpressed in ER-negative breast cancers (7). To detect sLex 
expression we chose the widely used HECA-452 monoclonal 
antibody that, in our hands, was able to recognize sLex carried 
by multiple glycoproteins and/or glycolipids (7). HECA-452 
binding is therefore non-discriminative of the carrier of the 
glycan. This is why we wanted to examine the relevance of 
sLex together with two of its described protein carriers in our 
Table III. Hazard ratios of survival according to single or combined variables.
 BCSSa DMFSb --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------
Variables Hazard ratio 95% Confidence interval Hazard ratio 95% Confidence interval
BST-2 3.654 1.362-9.801 3.961 1.379-11.380
BST-2/sLex  4.566 1.468-14.200 7.070 2.077-24.070
LGALS3BP 2.541 1.153-5.597 2.554 1.130-5.772
LGALS3BP/sLex 2.048 0.840-4.990 2.569 1.008-6.549
aBreast cancer specific survival; bdistant metastasis-free survival.
Figure 5. Organotropism of distant metastasis of ER-negative tumours 
according to high and low scores of sLex or its carriers. Frequencies of 
metastasis for each distant organ are indicated as % on top of each column. 
Dotted lines on each graph represent the average frequency for patients with 
ER-negative tumours.
Table IV. Adjuvant treatments of ER-negative patients.
 Treatment No. of patients
No chemotherapy None   1
n=29 Tamoxifen 28
Chemotherapy CMFa + Tamoxifen   6
n=28 CMF 13
 EFCb   5
 Other chemotoxicsc   4
aCyclophosphamide, methotrexate, 5-fluorouracil; bEpirubicin, 
cisplatin, 5-fluorouracil; cincludes EFC + Tamoxifen (1), Taxol (1), 
methotrexate and mitozantrone (1) and cyclophosphamide + TAM.
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statistical analyses. Since carbohydrate structures, or glycans, 
result from the combined expression of several synthesizing 
enzymes (glycosyltransferases), one of the most efficient way 
to assess their expression in tumour sample is to use specific 
probes (monoclonal antibodies or lectins) to detect them on 
tissue sections. Thus, to analyse both proteins and glycans from 
the same material, we chose to assess the expression of sLex 
and its putative carriers by immunohistochemistry. Another 
aim of our study was to investigate the possible correlation 
of our markers or combinations of markers with the organ-
otropism of the metastases. To achieve this, we exploited a 
series of formalin-fixed paraffin-embedded samples archived 
by the King's Health Partners Cancer Biobank, which consist 
of 400 patient biopsies all associated with the extensive 
clinical history (e.g. date and site of metastasis and treatment 
protocols) of the corresponding patients. From this series, 
we managed to validate scoring for all three markers for 249 
samples. Although this cohort was of modest size, the quality 
of the associated clinical data made it suitable for the purpose 
of our study.
Of note, we found that both BST-2 and LGALS3BP 
glycoproteins were indeed associated with the development of 
subsequent distant metastasis and also patient survival, albeit 
only in the patients with ER-negative tumours. Conversely, 
the expression of these proteins was not dependent on the 
ER-status of the tumours. This suggests that both proteins act 
on the pathway of metastasis in partnership with other factors 
that are potentially specific to ER-negative cancer cells.
One such factor could be the sLex antigen, which corre-
lates with ER negativity (7). We found that combining sLex 
and LGALS3BP high expression to stratify patients did not 
improve the prognostic significance of LGALS3BP. This 
suggests that the pro-metastatic function of LGALS3BP is not 
primarily due the ability of this protein to be recognised by 
E-selectin. Indeed, LGALS3BP (MAC-2BP) was experimen-
tally shown to be involved in pro-metastatic interactions (15,16) 
Figure 6. Correlation of combined expression of sLex with its carriers (BST-2 or LGALS3BP) with distant metastasis-free survival (DMFS) and breast cancer 
specific survival (BCSS) according to ER status (positive or negative). Number of patients included is indicated next to each DMFS curve. p-values were 
calculated using Grehan-Breslow-Wilcoxon test (Prism5).
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independently of sLex expression or selectin involvement. 
One previous study also reported LGALS3BP to be asso-
ciated with poor survival in node-negative breast cancer 
patients (17). On the contrary, another large study showed 
no correlation of the cytosolic expression of LGALS3BP 
with prognosis in breast cancer (19). However, the authors 
of this study argued that the cytosolic, immature, form of 
LGALS3BP may not be appropriate to predict prognosis due 
to the possible lack of biological activity. While implication 
of LGALS3BP in tumour progression and metastasis is now 
well documented in a number of cancers, it is also clear 
that the galectins/galectin binding protein/ligand networks 
involved are intricate and plastic (20). The present study 
confirms the clinical relevance of LGALS3BP by showing 
its association with occurrence of metastasis in ER-negative 
breast cancer, but dismisses sLex antigen as a mediator of 
this effect.
On the contrary, high-sLex/high-BST-2 combined 
expression was a better predictor of distant metastasis 
and survival than BST-2 alone. High expression of BST-2 
mRNA was previously associated with tumour aggressive-
ness and decreased survival in breast cancer by others (21). 
Cai et al also reported BST-2 protein expression to be 
associated with breast cancer bone metastasis in a smaller 
cohort (n=50) of breast samples (22). Experimental data, 
based on cell lines and in vivo models, have hinted that 
BST-2 was involved in increased proliferation and reduced 
apoptosis (23), as well as increased migration, invasion and 
metastasis (21,22,24). The data we are presenting imply that 
the role of BST-2 in metastasis is specific to patients with 
ER-negative tumours, and may be further enhanced by 
sLex expression. The reason why BST-2 appears to specifi-
cally influence the tropism of ER-negative breast cancers 
is unclear. It could be related to the described function of 
BST-2 as an organiser of membrane microdomains (i.e. lipid 
rafts) (25). Indeed, by acting on the organization of the cell 
membrane, oligomers of BST-2 may promote the function of 
other molecules, specifically expressed in ER-negative cancer 
cells compared to ER-positive ones, which are involved in 
brain or liver metastasis. Identifying such partners of BST-2 
Figure 7. Correlation of combined BST-2/LGALS3BP expression with distant 
metastasis-free survival (DMFS) and breast cancer-specific survival (BCSS) 
according to ER status. Number of patients included is indicated next to each 
DMFS curve. p-values were calculated using Grehan-Breslow-Wilcoxon test 
(Prism5).
Figure 8. Effect of adjuvant treatment protocols (no chemotherapy/black lines 
vs. chemotherapy/grey lines) on distant metastasis-free survival (DMFS) and 
breast cancer-specific survival (BCSS) of ER-negative patients, according 
to combined BST-2/sLex high expression (Plain lines). Number of patients 
included is indicated next to each DMFS curve.
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would thus warrant further investigations. Clusterisation 
of BST-2 around the lipid rafts would also create patches of 
BST-2 associated glycans, including sLex (25). Such organiza-
tion would indeed enhance the ability of BST-2 borne sLex 
to be recognised by selectin by improving the avidity of the 
interaction. Whether these putative mechanisms actually 
participate in the metastatic process in breast cancer would 
require further experimental demonstration.
The prognostic value of combined expression of BST-2 
and LGALS3BP was not improved compared to each marker 
individually. Thus, the synergistic effect of sLex and BST-2 
expression on prognosis is specific of these particular two 
markers, and not random. Importantly, due to the complex 
biosynthesis of glycans, such a combination of markers could 
not have been easily detected using gene profiling strategies 
on its own. Supporting this, one very recent study has demon-
strated that integrated analysis of glycosylation genes and 
their glycan products indeed resulted in significant prognostic 
data (26). In the same line, our present study demonstrates the 
potential of the widely available technique of immunohisto-
chemistry to investigate combinations of glycans together with 
relevant protein carriers as prognosis markers.
The combination of BST-2 expression and sLex positivity 
identified a small subset of patients that fared significantly 
worse than the other ER-negative breast cancer patients. 
Although sub-stratification ended up producing small groups 
of patients, the statistical analysis retained a high degree of 
significance. Whilst patients with ER-negative tumours may 
receive adjuvant chemotherapy, depending on other biological 
and patient variables, it is clear that not all of these women 
do equally badly (27). Based on new biomarkers, such as 
our BST-2/sLex combination, one may therefore consider 
improving ER-negative patients follow-up and treatment 
protocols with possibly more aggressive therapy. On the other 
hand, such biomarkers, presumably involved in selectin-
mediated metastasis (28), could also serve as molecular target 
for tailored therapy (29). In that regard, we believe both BST-2 
and LGALS3BP could be considered as putative targets to treat 
ER-negative metastatic breast cancer.
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